Bedrijf laden
Just reported
Q4 FY2026 results
From Cencora's results release of 4 november 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
US$ 88,35B
+5,5% y/y
+4,2% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$ 2,71
-31% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$ 906,8M
-19% q/q
Guided
—
No guide given
Company outlook
Full year 2027
- EPS, adjustedUS$ 19,40 – US$ 19,75First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Cencora is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Distribution
Graded A or B and worth $2B or more: A first, then the largest.
All 11 graded companies in its industry
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 okt 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 okt 2026BAGraded B, now A
Gebouwd uit de eigen deponeringen van Cencora, Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
